- Home
- NRIX vs HUYA Comparison
NRIX vs HUYA Comparison
Compare NRIX & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- HUYA
- Stock Information
- Founded
- NRIX 2009
- HUYA 2014
- Country
- NRIX United States
- HUYA China
- Employees
- NRIX N/A
- HUYA N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- HUYA Computer Software: Programming Data Processing
- Sector
- NRIX Health Care
- HUYA Technology
- Exchange
- NRIX Nasdaq
- HUYA Nasdaq
- Market Cap
- NRIX 908.0M
- HUYA 827.0M
- IPO Year
- NRIX 2020
- HUYA 2018
- Fundamental
- Price
- NRIX $11.64
- HUYA $3.52
- Analyst Decision
- NRIX Strong Buy
- HUYA Buy
- Analyst Count
- NRIX 16
- HUYA 3
- Target Price
- NRIX $30.44
- HUYA $4.57
- AVG Volume (30 Days)
- NRIX 857.7K
- HUYA 1.7M
- Earning Date
- NRIX 07-10-2025
- HUYA 08-12-2025
- Dividend Yield
- NRIX N/A
- HUYA 29.99%
- EPS Growth
- NRIX N/A
- HUYA N/A
- EPS
- NRIX N/A
- HUYA N/A
- Revenue
- NRIX $56,417,000.00
- HUYA $838,372,907.00
- Revenue This Year
- NRIX $16.69
- HUYA $5.82
- Revenue Next Year
- NRIX N/A
- HUYA $4.20
- P/E Ratio
- NRIX N/A
- HUYA N/A
- Revenue Growth
- NRIX N/A
- HUYA N/A
- 52 Week Low
- NRIX $8.18
- HUYA $2.82
- 52 Week High
- NRIX $29.56
- HUYA $6.43
- Technical
- Relative Strength Index (RSI)
- NRIX 54.44
- HUYA 37.40
- Support Level
- NRIX $11.17
- HUYA $3.53
- Resistance Level
- NRIX $11.99
- HUYA $3.80
- Average True Range (ATR)
- NRIX 0.58
- HUYA 0.16
- MACD
- NRIX -0.07
- HUYA -0.05
- Stochastic Oscillator
- NRIX 37.50
- HUYA 6.02
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Established in 2011, Huya is the largest online game livestreaming company in China. Headquartered in Guangzhou, Huya mainly provides livestreamed videos on esports games such as League of Legends and Honor of Kings and collects virtual tips from viewers. Its products include the Huya Live platform in China and Nimo TV in Southeast Asia and South America. As of 2024, Huya was a subsidiary of Tencent, which owned 63% of its equity stake and held 94% of the voting power.